[go: up one dir, main page]

HK1060519A1 - Compositions containing alpha-2-adrenergic agonist components - Google Patents

Compositions containing alpha-2-adrenergic agonist components

Info

Publication number
HK1060519A1
HK1060519A1 HK04103520.9A HK04103520A HK1060519A1 HK 1060519 A1 HK1060519 A1 HK 1060519A1 HK 04103520 A HK04103520 A HK 04103520A HK 1060519 A1 HK1060519 A1 HK 1060519A1
Authority
HK
Hong Kong
Prior art keywords
adrenergic agonist
alpha
components
agonist components
compositions containing
Prior art date
Application number
HK04103520.9A
Other languages
English (en)
Inventor
Orest Olejnik
Edward D S Kerslake
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22814143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1060519(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1060519A1 publication Critical patent/HK1060519A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK04103520.9A 2000-07-14 2004-05-18 Compositions containing alpha-2-adrenergic agonist components HK1060519A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21820000P 2000-07-14 2000-07-14
PCT/US2001/021552 WO2002005853A2 (en) 2000-07-14 2001-07-09 Compositions containing alpha-2-adrenergic agonist components

Publications (1)

Publication Number Publication Date
HK1060519A1 true HK1060519A1 (en) 2004-08-13

Family

ID=22814143

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103520.9A HK1060519A1 (en) 2000-07-14 2004-05-18 Compositions containing alpha-2-adrenergic agonist components

Country Status (20)

Country Link
US (4) US6627210B2 (pt)
EP (1) EP1365811A2 (pt)
JP (3) JP4927298B2 (pt)
KR (1) KR100757656B1 (pt)
CN (2) CN101897704B (pt)
AR (1) AR033539A1 (pt)
AU (2) AU7326901A (pt)
BR (1) BR0109317A (pt)
CA (1) CA2402405C (pt)
HK (1) HK1060519A1 (pt)
HU (1) HUP0303197A3 (pt)
IL (2) IL151530A0 (pt)
MX (1) MXPA02008930A (pt)
NO (1) NO333367B1 (pt)
NZ (1) NZ521185A (pt)
PL (1) PL360707A1 (pt)
RU (1) RU2311928C2 (pt)
TW (1) TWI287998B (pt)
WO (1) WO2002005853A2 (pt)
ZA (1) ZA200207413B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4927298B2 (ja) * 2000-07-14 2012-05-09 アラーガン、インコーポレイテッド α−２−アドレナリンアゴニスト成分を含有する組成物
KR20030023700A (ko) * 2000-07-14 2003-03-19 알러간, 인코포레이티드 치료활성 성분을 함유하고 용해도가 증강된 조성물
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
AU2011250793B2 (en) * 2000-07-14 2012-11-29 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
JP2004528369A (ja) * 2001-05-03 2004-09-16 アラーガン、インコーポレイテッド 向上した薬物動態特性を有する組成物
US6753017B2 (en) * 2001-11-07 2004-06-22 Jrs Pharma Lp Process for preparing dry extracts
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US6982079B2 (en) * 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
JP2006504741A (ja) * 2002-10-08 2006-02-09 アラーガン、インコーポレイテッド 痴呆およびパーキンソン病の処置における（２−イミダゾリン−２−イルアミノ）キノキサリンの使用方法
CN100431536C (zh) * 2002-10-08 2008-11-12 阿勒根公司 用于治疗神经变性的α2B或α2B/2C肾上腺素能受体激动剂
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
PL1654002T5 (pl) * 2003-08-07 2014-06-30 Allergan Inc Kompozycje do dostarczania środków terapeutycznych do oczu
EP1692444A2 (en) * 2003-10-24 2006-08-23 J. Rettenmaier & Söhne GmbH + Co. KG Process for co-spray drying agents with dry silicified mcc
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
CA2567401C (en) * 2004-05-25 2013-11-12 Sansrosa Pharmaceutical Development, Inc. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
JP4789454B2 (ja) * 2004-12-03 2011-10-12 株式会社キーエンス 蛍光顕微鏡
US20060228487A1 (en) * 2005-04-11 2006-10-12 J. Rettenmaier & Söehne GmbH + Co. KG Methods of combining active agents with augmented microcrystalline cellulose
PE20070336A1 (es) * 2005-08-25 2007-04-16 Schering Corp Compuestos de indolina como agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
US7700592B2 (en) * 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
US8003624B2 (en) * 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
US20070093477A1 (en) * 2005-08-25 2007-04-26 Schering Corporation And Pharmacopeia Drug Discovery, Inc. Alpha2C adrenoreceptor agonists
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
CN101878029B (zh) * 2008-02-15 2013-04-03 骨治疗公司 用于治疗和/或预防骨关节病的药物组合物
BRPI0905715A2 (pt) * 2008-02-15 2015-07-14 Bone Therapeutics Composição farmacêutica e kit de componentes
US9192571B2 (en) 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US20120156244A1 (en) * 2008-08-01 2012-06-21 Alpha Synergy Development Inc. Nasal Compositions and Uses Thereof
US8080550B2 (en) * 2008-08-01 2011-12-20 Alpha Synergy Development, Inc. Anesthetic compositions and methods of use
EP2323734A1 (en) * 2008-08-04 2011-05-25 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
AR073628A1 (es) 2008-10-07 2010-11-17 Schering Corp Analogos de biaril espiroaminooxazolina y espiroaminodiazolina moduladores de receptores adrenergicos alfa2c, composiciones farmaceuticas que los comprenden y uso de los mismos en rinitis alergica,trastornos cardiacos y otras enfermedades
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
ES2695931T3 (es) 2009-11-09 2019-01-11 Allergan Inc Composiciones y métodos para estimular el crecimiento del pelo
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
EP2525776B1 (en) 2010-01-22 2015-10-28 Allergan, Inc. Intracameral sustained release therapeutic agent implants
PL2552449T3 (pl) 2010-03-26 2017-09-29 Galderma Research & Development Kompozycje zawierające brymonidynę do leczenia rumienia
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
RU2014119879A (ru) 2011-10-19 2015-11-27 Галдерма С.А. Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5
CN109602691A (zh) 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CA2926515C (en) 2013-10-31 2020-11-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
ES2818073T3 (es) 2013-12-24 2021-04-09 Sentiss Pharma Private Ltd Solución oftálmica de tartrato de brimonidina tópica
EP4420726A3 (en) * 2015-03-19 2024-11-13 Allergan, Inc. Fixed dose combination of bromonidine and timolol
WO2018031973A1 (en) 2016-08-12 2018-02-15 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
US11185532B2 (en) 2019-05-01 2021-11-30 Clexio Biosciences Ltd. Methods of treating pruritus
KR102678138B1 (ko) 2022-09-29 2024-06-25 주식회사태준제약 브리모니딘을 포함하는 안과용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154119B (de) * 1961-11-30 1963-09-12 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 2-(2', 4', 6'-Trimethylbenzyl)-1, 3-diazacyclopenten-(2) und seinen Salzen
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4530920A (en) 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
GB9017353D0 (en) 1990-08-08 1990-09-19 Merck Sharp & Dohme Chemical process
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
JPH05271053A (ja) * 1992-03-27 1993-10-19 Lion Corp 安定な点眼剤
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
WO1994016685A1 (en) 1993-01-28 1994-08-04 University Of Iowa Research Foundation Ophthalmic uses of signa agonists
EP1285657A3 (en) 1993-10-13 2003-08-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5994110A (en) 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
ZA965837B (en) 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
EP0834308A1 (en) 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
WO1998047878A1 (en) 1997-04-18 1998-10-29 Abbott Laboratories A process for the preparation of highly pure 6,7-dichloro-5- nitro-2,3-dihydroquinoxaline-2,3-dione
MY116782A (en) * 1997-12-22 2004-03-31 Otsuka Pharma Co Ltd Water-soluble eye drop
WO1999043299A2 (en) 1998-02-26 1999-09-02 Abbott Laboratories Oral formulation for hydrophilic drugs
PT1069913E (pt) 1998-04-07 2003-11-28 Alcon Mfg Ltd Composicoes oftalmicas gelificantes contendo goma xantana
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
DE69923987T2 (de) 1998-10-08 2006-11-02 Karagoezian, Hampar L., San Juan Capistrano Synergistische antimikrobielle, dermatologische und ophtahalmologische zubereitung, die ein chlorit und wasserstoffperoxid enthalten
IN185228B (pt) * 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
JP4927298B2 (ja) * 2000-07-14 2012-05-09 アラーガン、インコーポレイテッド α−２−アドレナリンアゴニスト成分を含有する組成物
KR20030023700A (ko) * 2000-07-14 2003-03-19 알러간, 인코포레이티드 치료활성 성분을 함유하고 용해도가 증강된 조성물

Also Published As

Publication number Publication date
IL151530A0 (en) 2003-04-10
IL151530A (en) 2009-05-04
CN100569291C (zh) 2009-12-16
CN1460026A (zh) 2003-12-03
NZ521185A (en) 2005-02-25
JP4927298B2 (ja) 2012-05-09
TWI287998B (en) 2007-10-11
WO2002005853A2 (en) 2002-01-24
AU7326901A (en) 2002-01-30
US20030087893A1 (en) 2003-05-08
KR100757656B1 (ko) 2007-09-10
BR0109317A (pt) 2003-06-17
PL360707A1 (en) 2004-09-20
WO2002005853A3 (en) 2003-09-12
CN101897704A (zh) 2010-12-01
NO20024221L (no) 2002-10-28
RU2311928C2 (ru) 2007-12-10
HUP0303197A3 (en) 2008-03-28
CA2402405C (en) 2008-02-12
AR033539A1 (es) 2003-12-26
US20040063689A1 (en) 2004-04-01
CA2402405A1 (en) 2002-01-24
NO333367B1 (no) 2013-05-13
US20030027811A1 (en) 2003-02-06
US6673337B2 (en) 2004-01-06
NO20024221D0 (no) 2002-09-04
KR20030017500A (ko) 2003-03-03
US20020032201A1 (en) 2002-03-14
MXPA02008930A (es) 2003-03-31
US6641834B2 (en) 2003-11-04
EP1365811A2 (en) 2003-12-03
HUP0303197A2 (hu) 2003-12-29
ZA200207413B (en) 2004-04-08
JP2008231122A (ja) 2008-10-02
AU2001273269B2 (en) 2005-08-11
US6627210B2 (en) 2003-09-30
JP2012067128A (ja) 2012-04-05
CN101897704B (zh) 2014-10-29
JP2004504279A (ja) 2004-02-12

Similar Documents

Publication Publication Date Title
HK1060519A1 (en) Compositions containing alpha-2-adrenergic agonist components
MY136097A (en) Methods for treating osteoarthritis using an estrogen agonist/antagonist
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
EA200300580A1 (ru) Соединения лактама
AP2001002225A0 (en) 1-heterocycle substituted diarylamines.
GB2387696A (en) Real-time odds-based gaming
UY26970A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos
GB2411467A (en) Method and apparatus for quantifying tissue histology
EP1590471A4 (en) COMPOSITIONS, METHODS AND SYSTEMS OF INFERENCE RELATING TO CATTLE CHARACTERISTICS
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
UY26451A1 (es) Procedimiento para la obtención de 1,2,3,4- tetrahidroquinolinas 4-carboxiamino-2-sustituidas
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
PL351593A1 (en) Substantially oil−free cyclosporin compositions
MX2007002383A (es) Composiciones que contienen componentes agonistas alfa-2-adrenergicos.
MXPA04001785A (es) Benzofurano y derivados de dihidrobenzofurano utiles como agonistas de beta-3 adrenoreceptores.
TWI256304B (en) Pharmaceutical compositions based on azetidine derivatives
MXPA03009048A (es) Agonistas de la somatostatina.
EP1210951A3 (en) Combination for treating andropause containing estrogen agonists/antagonists and testosterone
TW200517117A (en) Stabilized compositions containing an oxygen-labile active agent
MY124078A (en) Eletriptan hydrobromide monohydrate
GB9918429D0 (en) Organic compounds
TW200501964A (en) Lipid-regulating agent and its usage
LT2003075A (en) Inhibitor of monoamine uptake

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20210713